Christine Pevitt Algrant. modern Y...
Christine Pevitt Algrant. modern York: Grove, 2002. 338 pp $2700
Madame de Pompadour. Evelyne Lever Trans. Catherine Temerson recent York: Farrar, Straus & Giroux, 2002 310 pp $2600
Madame de Pompadour: Image of a Mistress. Colin Jone modern Haven: Yale UP, 2002 76 pp $3500
"Evelyne Lever's 'Madame De Pompadour,' translated from the French by means of Catherine Temerson, and Christine Pevitt Algrant's 'Madame de Pompadour: Mistress of France' are compact, sympathetic lives aimed at an intelligent popular readership. Lever's portrait is more revealing of
Other Articles
-Morphotek will collaborat...-Eksigent Technologies nam...
-The benefits of outsourci...
-Sartorius Corporation ...
-In our previous column, w...
-Efoora appointed Michael ...
-Affymax appointed Anne-Ma...
-Traditionally, continuous...
-New Brunswick Scientific ...
-The German-American firm ...
-Don G. Burstyn, formerly ...
-American patients are mor...
-Summary Prior to va...
-BioPharm Editorial Adviso...
-Australia agreed to spend...
-The Biotechnology Industr...
-Ambion, The RNA Company i...
-Therapies based on living...
-A recent survey found tha...
-ViroLogic will acquire Ac...
-Cardinal Health named Joh...
-One of the greatest chall...
-As the president of a sma...
-Sweden-based Biovitrum wi...
-Nanogen appointed David L...
-The Experion Process Know...
-Although biomedical resea...
-The Supreme Court of Cana...
-Netherlands-based DSM Bio...
-David A. Smoller joined S...
-A few months ago, I wrote...
-Panacos Pharmaceuticals w...
-Karen K. Vaccaro will res...
-Acceleron Pharma appointe...
-Two quarterly meetings of...
-Illinois-based Abbot Labo...
-FKI Logistics announced t...
-The following corrections...
-It its widest definition,...
-UK-based Xcellsyz will li...
-Andrew P. Aromando joined...
-Invitrogen's comprehensiv...
-Last month, we described ...
-The Swiss life sciences c...
-Protein Design Labs (PDL)...
-Model It HNMR, the newest...
-Tech transfer, like chang...
-QLT and Atrix Laboratorie...
-Dendreon announced Christ...
-Baxter Pharmaceutical Sol...
-The biopharmaceutical ind...
-GlaxoSmithKline announced...
-Montreal-based Caprion Ph...
-Xenova Group recently ann...
-Cole-Parmer's new 192-pag...
-Over the last decade ther...
-Benchmark your facility p...
-As biotechnology organiza...
-Frederick D. Sancillo, fo...
-Insmed acquired a recombi...
-Baxter Pharmaceutical Sol...
-Model It HNMR, the newest...
-DA's regulation 21 CFR Pa...
-Robert P. Ryan joined Ath...
-A new report from Busines...
-Biotest offers a complete...
-Swagelok offers a brochur...
-Partnering is a global ph...
-Human Genome Sciences CEO...
-Shorten the process devel...
-The licensure of biotechn...
-Rodger Currie joined Amge...
-The GEA Filtration Model ...
-A multi-channel chemistry...
-From June 6-9, San Franci...
-Skanska USA Building Inc....
-New Brunswick Scientific'...
-AVI BioPharma appointed P...
-Ambion, The RNA Company, ...
-"If you want to be a...
-Xcellerex appointed Susan...
-Researchers identified th...
-Cool Spring Business Park...
-In October 2003, Shenzhen...
-Laureate Pharma appointed...
-After a 6-5 vote by Calif...
-QSourcing, a service of Q...
-The recent discovery of &...
-Affymax added Douglas L. ...
-USDA recently approved tw...
-BioPharm International is...
-Serologicals has released...
-This document by Shenzhen...
-Robert Bronstein joined A...
-Gloucester Gains Fujisawa...
-With more than 30 years o...
-Pall's SUPRAdisc II depth...
-In today's competitive ma...
-Protein Design Labs repor...
-Charles A. Rice will repl...
-AstraZeneca's Faslodex (f...